Monday June 26th 2017

Archive for October, 2011

MS patient doesn’t see miracle after surgery

MS patient doesn’t see miracle after surgery

Barrie’s Spencer Ross is back to work after heading to the United States recently for CCSVI surgery, but his Multiple Scleroris symptoms are still there. Ross was on a waiting list for the Chronic Cerebral Spinal Venous Insufficiency (CCSVI) in Albany, New York, but his [Read More]

Montel Williams discusses controversial MS treatment

Montel Williams discusses controversial MS treatment

Having spent much of his adult life coping with multiple sclerosis and trying various medical options, former talk show host Montel Williams decided an experimental — and controversial — treatment was worth the risk: liberation therapy. “The only way I can [Read More]

Letters: Thank Dr. McDonald for MS treatment

Letters: Thank Dr. McDonald for MS treatment

Thank you Dr. Sandy McDonald. Finally, someone is taking the bull by the horns and is actually going to properly investigate this ‘liberation’ treatment. I have had multiple sclerosis for the past 29 years and was lucky enough to undergo the treatment in New [Read More]

 Page 1 of 4  1  2  3  4 »

Latest Topics

Are static and functional balance abilities related in individuals with Multiple Sclerosis? – Pau M, Porta M, Coghe G, Corona F, Pilloni G, Lorefice…

Are static and functional balance abilities related in individuals with Multiple Sclerosis? – Pau M, Porta M, Coghe G, Corona F, Pilloni G, Lorefice…

BACKGROUND: In people with Multiple Sclerosis (pwMS), balance assessment is essential in estimating the risk of falls, [Read More]

CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis

CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis

The European Medicines Agency ’ s Committee for Medicinal Products for Human Use recommends approval of cladribine to [Read More]

Germany’s Merck gets EU backing for oral MS drug

Germany’s Merck gets EU backing for oral MS drug

FRANKFURT (Reuters) - Germany's Merck KGaA has won a key recommendation to become a late entrant to the market for oral [Read More]

New data at EAN show Roche ’s OCREVUS (ocrelizumab) significantly reduced multiple measures of disease progression in relapsing and primary…

New data at EAN show Roche ’s OCREVUS (ocrelizumab) significantly reduced multiple measures of disease progression in relapsing and primary…

Roche announced today that new post-hoc analyses from the OCREVUS ™ (ocrelizumab) Phase III clinical trial programme [Read More]

MS Society Hosts Joint Congressional Briefing on the Value of Rehabilitation

MS Society Hosts Joint Congressional Briefing on the Value of Rehabilitation

/About-the-Society/News/Society-Hosts-Joint-Congressional-Briefing-on-the [Read More]